193 related articles for article (PubMed ID: 12904741)
21. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
Kunimoto D; Warman A; Beckon A; Doering D; Melenka L
Clin Infect Dis; 2003 Jun; 36(12):e158-61. PubMed ID: 12802781
[TBL] [Abstract][Full Text] [Related]
22. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Can Commun Dis Rep; 2001 Jul; 27(13):114-6. PubMed ID: 11443837
[No Abstract] [Full Text] [Related]
23. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
24. Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study.
Hagiwara E; Suido Y; Asaoka M; Katano T; Okuda R; Sekine A; Kitamura H; Baba T; Komatsu S; Ogura T
J Infect Chemother; 2019 Dec; 25(12):1026-1030. PubMed ID: 31229376
[TBL] [Abstract][Full Text] [Related]
25. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
26. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons.
Lobato MN; Reves RR; Jasmer RM; Grabau JC; Bock NN; Shang N;
Chest; 2005 Apr; 127(4):1296-303. PubMed ID: 15821208
[TBL] [Abstract][Full Text] [Related]
27. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
[TBL] [Abstract][Full Text] [Related]
28. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers.
Burman WJ; Reves RR
Am J Respir Crit Care Med; 2001 Oct; 164(7):1112-3. PubMed ID: 11673194
[No Abstract] [Full Text] [Related]
29. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
30. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
Stout JE
Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
[TBL] [Abstract][Full Text] [Related]
31. [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].
Camacho A; Pérez-Camacho I; Rivero A; Natera C; García-Lázaro M; Castón JJ; Gallo M; Kindelán JM; Torre-Cisneros J
Enferm Infecc Microbiol Clin; 2010 Apr; 28(4):239-44. PubMed ID: 19647900
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.
Lee AM; Mennone JZ; Jones RC; Paul WS
Int J Tuberc Lung Dis; 2002 Nov; 6(11):995-1000. PubMed ID: 12475146
[TBL] [Abstract][Full Text] [Related]
33. Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection.
Ijaz K; McElroy PD; Jereb J; Navin TR; Castro KG
Clin Infect Dis; 2007 Feb; 44(3):464-5; author reply 465. PubMed ID: 17205462
[No Abstract] [Full Text] [Related]
34. Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
Garca-Doval I
J Am Acad Dermatol; 2004 May; 50(5):801; author reply 801-2. PubMed ID: 15097974
[No Abstract] [Full Text] [Related]
35. US guidelines for treatment of latent tuberculosis revised.
McCarthy M
Lancet; 2001 Sep; 358(9284):816. PubMed ID: 11564495
[No Abstract] [Full Text] [Related]
36. Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis.
Medinger A
Chest; 2002 May; 121(5):1710-2. PubMed ID: 12006469
[TBL] [Abstract][Full Text] [Related]
37. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention.
MMWR Recomm Rep; 1998 Oct; 47(RR-20):1-58. PubMed ID: 9809743
[TBL] [Abstract][Full Text] [Related]
38. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Ijaz K; McElroy PD; Navin TR
Clin Infect Dis; 2004 Jul; 39(2):289. PubMed ID: 15307044
[No Abstract] [Full Text] [Related]
39. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis.
Younossian AB; Rochat T; Ketterer JP; Wacker J; Janssens JP
Eur Respir J; 2005 Sep; 26(3):462-4. PubMed ID: 16135729
[TBL] [Abstract][Full Text] [Related]
40. Treatment of latent tuberculosis infection: a network meta-analysis.
Stagg HR; Zenner D; Harris RJ; Muñoz L; Lipman MC; Abubakar I
Ann Intern Med; 2014 Sep; 161(6):419-28. PubMed ID: 25111745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]